Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FDA

FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ

According to a U.S. health regulator, asking people to get COVID-19 boosters frequently wasn't sustainable because of vaccine fatigue, and authorities needed to develop a long-term strategy for protection against the evolving virus.

Benzinga

The high-stakes push to get COVID vaccines to young children

The Omicron variant and and anti-vaccine backlash are complicating the effort.

Axios

These 3 Psychedelic Stocks Will Benefit When The FDA Green-Lights MDMA (Molly, Ecstasy)

What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted therapy.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…

Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales and development agreement.

Benzinga

US experts discuss COVID boosters for the fall and beyond

Vaccine experts are meeting to discuss the U.S. strategy for future COVID-19 booster campaigns

The Independent UK

Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial

Citius Pharmaceuticals Inc (NASDAQ:CTXR) reported topline results from the Phase 3 trial of I/ONTAK (E7777) for persistent or recurrent cutaneous T-cell lymphoma (CTCL). I/ONTAK (E7777) is an engineered IL-2-diphtheria toxin fusion protein. No new safety signals were identified. Citius anticipates filing a marketing application with the FDA in 2H of 2022. The Independent…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

States weigh shielding doctors' COVID misinformation, unproven remedies

The controversy began in September, more than a year into the pandemic, when the Tennessee Board of Medical Examiners issued a warning to doctors in the state: Spreading misinformation about COVID-19 vaccines could land them in big trouble with the board, including the possible revocation of their medical licenses.

Tribune News Service

Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication

The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

Benzinga

FDA Approves BioXcel's Igalmi - First Orally Dissolving Sublingual Film For Schizophrenia-Associated Agitation

The

Benzinga

Repurposing generic drugs can reduce time and cost to develop new treatments – but low profitability remains a barrier

Discovering new ways to use existing drugs can come about intentionally or by chance.

The Conversation

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Iovance Outlines Frontline Melanoma Strategy For Lifileucel / Pembrolizumab Combo Therapy

The

Benzinga

Experts eye a new game plan for COVID vaccines

An FDA panel mulls long-term strategy for COVID shots

Axios

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Future of COVID boosters comes down to crucial meeting of FDA Advisers

An all-star panel of COVID-19 experts will convene this week to hash out how and when vaccines should be updated to address future variants as the virus continues to rapidly mutate.

The Independent UK

US pulls GSK's COVID drug as omicron sibling dominates cases

U.S. regulators say GlaxoSmithKline’s COVID-19 antibody drug should no longer be used because it is likely ineffective against the latest version of the virus that accounts for most cases

Reason

Under Oregon's Proposed Rules, Legal Psilocybin Will Be All-Natural, Organic, and GMO-Free

The state's regulators plan to start accepting applications from manufacturers and "service centers" on January 2.

Benzinga

MindMed Appoints Francois Lilienthal As New CCO

With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. (NASDAQ:MNMD) as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months. Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Nasdaq-Listed Field Trip Gets First Patent Approved For Improved Psychedelic Drug

Field Trip Health Ltd. (NASDAQ:FTRP), a biotech and care delivery company in the psychedelics space, has been granted its first patent by the U.S. Patent and Trademark Office. The patent covers claims around FT-104, the company’s flagship proprietary psychedelic molecule, for composition of matter, use and manufacturing of the compound…

Benzinga

Allergan Shares Topline Data For Twice Daily Vuity (Pilocarpine) In Blurry Vision Study

Allergan, an AbbVie Inc (NYSE: ABBV) company, announced topline data from Phase 3 VIRGO trial evaluating Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia, age-related blurry near vision.

Benzinga

Bluebird Bio Joins Layoff Band Wagon As Gene Therapy Biotech Cuts Staff To Reduce Costs

Bluebird Bio Inc (NASDAQ:BLUE) is laying off about 30% of its workforce before the FDA decides the fate of two of its gene therapies. The gene therapy-focused company is showing the exit to nearly one-third of its staff to extend its cash runway into the first half of 2023 and save $160 million…

Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel

Here's a roundup of top developments in the biotech space over the last 24 hours:

Roll Call

Michigan Rep. Fred Upton announces plan to retire - Roll Call

A former chairman of the Energy and Commerce Committee, Upton faced a primary against a fellow Republican because of redistricting.

Benzinga

From Pharma To Psychedelics, Robert Barrow, CEO Of MindMed: Meet Our Speakers

With over ten years of experience in the pharmaceutical industry, Robert Barrow, CEO of Mind Medicine Inc. (NASDAQ:MNMD) is someone who certainly knows the ins and outs of the business. Barrow joined MindMed in January 2021 as Chief Development Officer (CDO) but was later appointed as CEO and member of…

Benzinga

It's Official: House Approves Bill To Further Expand Medical Marijuana Research

The House of Representatives passed the Medical Marijuana Research Act, which will substantially expand scientific research on marijuana, including allowing scientists to study products from dispensaries.

1 … 177 178 179 180

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

House of Representatives

Securities and Exchange Commission

Ohio State University

91 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.